124 related articles for article (PubMed ID: 36344487)
1. Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells.
Mun JY; Baek SW; Jeong MS; Jang IH; Lee SR; You JY; Kim JA; Yang GE; Choi YH; Kim TN; Chu IS; Leem SH
Cell Death Discov; 2022 Nov; 8(1):450. PubMed ID: 36344487
[TBL] [Abstract][Full Text] [Related]
2. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
Li Y; Zu X; Hu X; Wang L; He W
Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
[TBL] [Abstract][Full Text] [Related]
3. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
[TBL] [Abstract][Full Text] [Related]
4. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
6. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
7. Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma.
Chen S; Yang M; Wang C; Ouyang Y; Chen X; Bai J; Hu Y; Song M; Zhang S; Zhang Q
Cancer Lett; 2021 Apr; 503():43-53. PubMed ID: 33352248
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of
Azhati B; Maolakuerban N; Ma T; Li X; Rexiati M
Arch Med Sci; 2020; 16(5):1207-1217. PubMed ID: 32864010
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.
Kozinn SI; Harty NJ; Delong JM; Deliyiannis C; Logvinenko T; Summerhayes IC; Libertino JA; Holway AH; Rieger-Christ KM
Genes Cancer; 2013 Jan; 4(1-2):61-9. PubMed ID: 23946872
[TBL] [Abstract][Full Text] [Related]
10. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA
Chen X; Xie R; Gu P; Huang M; Han J; Dong W; Xie W; Wang B; He W; Zhong G; Chen Z; Huang J; Lin T
Clin Cancer Res; 2019 Feb; 25(4):1389-1403. PubMed ID: 30397178
[TBL] [Abstract][Full Text] [Related]
12. Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.
Vallo S; Rutz J; Kautsch M; Winkelmann R; Michaelis M; Wezel F; Bartsch G; Haferkamp A; Rothweiler F; Blaheta RA; Cinatl J
Oncol Lett; 2017 Nov; 14(5):5513-5518. PubMed ID: 29113179
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis.
Liu X; Liu X; Wu Y; Fang Z; Wu Q; Wu C; Hao Y; Yang X; Zhao J; Li J; Wang Q; Yang Z; Xu J; Hu X; Tan M; Li L
Cell Physiol Biochem; 2018; 48(1):87-98. PubMed ID: 30001529
[TBL] [Abstract][Full Text] [Related]
14. Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer.
Lin F; Li X; Wang X; Sun H; Wang Z; Wang X
J Exp Clin Cancer Res; 2022 Apr; 41(1):129. PubMed ID: 35392966
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine.
Yu Y; Ding F; Gao M; Jia YF; Ren L
Oncol Lett; 2019 Sep; 18(3):3065-3071. PubMed ID: 31452783
[TBL] [Abstract][Full Text] [Related]
16. JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells.
Ojha R; Singh SK; Bhattacharyya S
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2484-2497. PubMed ID: 27474203
[TBL] [Abstract][Full Text] [Related]
17. The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics.
Zhu Y; Piao C; Zhang Z; Jiang Y; Kong C
Genomics; 2022 Jan; 114(1):125-137. PubMed ID: 34843906
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.
Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L
J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
20. Silencing of
Asai S; Miura N; Sawada Y; Noda T; Kikugawa T; Tanji N; Saika T
Oncol Lett; 2018 Jan; 15(1):522-527. PubMed ID: 29391886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]